Flutrimazole

Summary

Flutrimazole (CHEMBL2107430) is an approved small-molecule EC 1.14.13.70 (sterol 14α-demethylase) inhibitor (ATC D01AC16).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: D01AC16 (+1 more)
• Chemistry: 346.4 Da · C22H16F2N2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2107430
Name	Flutrimazole
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	3401
ChEBI	CHEBI:82864
ATC	D01AC16, G01AF18
Molecular formula	C22H16F2N2
Molecular weight	346.4
InChIKey	QHMWCHQXCUNUAK-UHFFFAOYSA-N

SMILES: C1=CC=C(C=C1)C(C2=CC=C(C=C2)F)(C3=CC=CC=C3F)N4C=CN=C4

IUPAC name: 1-[(2-fluorophenyl)-(4-fluorophenyl)-phenylmethyl]imidazole

ChEBI definition: An imidazole antifungal agent that is imidazole in which the hydrogen attached to the nitrogen is replaced by a 2,4’-difluorotrityl group. A topical antifungal agent which displays potent broad-spectrum in vitro activity against dermatophytes, filamentous fungi and yeasts.

Pharmacological roles (ChEBI): EC 1.14.13.70 (sterol 14α-demethylase) inhibitor.

Also known as: Flutrimazol, Flutrimazole, Micetal, UR-4056, FLUTRIMAZOLE, flutrimazole

Patent coverage: 790 distinct patent families (2,604 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 2,435 (94%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 9 (assay-derived). Sample: Bile acid receptor, Thromboxane A2 receptor, Motilin receptor, Kappa-type opioid receptor, Sodium-dependent dopamine transporter, Voltage-gated inwardly rectifying potassium channel KCNH2, Adenosine receptor A3, Gastrin/cholecystokinin type B receptor, Nuclear receptor subfamily 1 group I member 2.

Bioactivity

ChEMBL activities: 5 potent at pChembl ≥ 5 of 11 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
NR1I2	6.44	AC50	360	nM	CHEMBL_ACT_25224634
NR1I2	6.25	AC50	560	nM	CHEMBL_ACT_25188603
OPRK1	6.03	AC50	930	nM	CHEMBL_ACT_25129980
KCNH2	5.78	AC50	1680	nM	CHEMBL_ACT_25118730
NR1I2	5.21	EC50	6100	nM	CHEMBL_ACT_13362895

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).